Drug intelligence / Profile preview

BNSO-001

Development stage
Unknown
Lead developer
BNS Ophthalmics
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Ophthalmic
01

Overview

BNSO-001 is a topical ophthalmic nanoparticle-based emulsion of tacrolimus being developed by BNS Ophthalmics, a joint venture between RAFARM and BioNanoSim. It utilizes BioNanoSim's proprietary nanotechnology platform (NTPO) to enhance the delivery, stability, and bioactivity of tacrolimus in ocular tissues. Tacrolimus is a potent immunosuppressive agent that acts as a calcineurin inhibitor, reducing the production of inflammatory cytokines. BNSO-001 is specifically designed for the treatment of chronic anterior uveitis, an inflammatory condition of the eye. The drug has received FDA Orphan Drug Designation and is being evaluated via an accelerated 505(b)(2) regulatory pathway, with Phase I/IIa clinical trials initiated in 2023.

Other names
tacrolimus ocular emulsion
02

Targets

FKBP1ACN (Calcineurin)

Beyond the preview

Go deeper on BNSO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNSO-001.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call